Medistim Third Quarter 2022 Results: Revenue Exceeds Expectations


Medistim (OB:MEDI) Third Quarter 2022 Results

Main financial results

  • Turnover: 116.5 million kr (up 14% compared to Q3 2021).
  • Net income: 24.6 million kr (up 31% compared to Q3 2021).
  • Profit margin: 21% (compared to 18% in the 3rd quarter of 2021).
    • The increase in the margin is explained by the increase in revenues.
OB:MEDI Earnings and Revenue Growth October 30, 2022

All figures shown in the table above are for the 12 month period (TTM)

Medistim EPS exceeds expectations, revenues are insufficient

Revenue beat analysts’ estimates by 3.7%.

Going forward, revenues are expected to grow by an average of 7.4% per year over the next 3 years, compared to a growth forecast of 7.3% for the medical device industry in Europe.

Market performance in Norway.

Shares of the company are up 14% from a week ago.

Risk analysis

Before concluding, we discovered 1 warning sign for Medistim of which you should be aware.

Valuation is complex, but we help make it simple.

Find out if Medistim is potentially overvalued or undervalued by viewing our full analysis, which includes fair value estimates, risks and warnings, dividends, insider trading and financial health.

See the free analysis

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.


Comments are closed.